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Editorial on the Research Topic
Early Genetic and Clinical Diagnosis in MEN1
Multiple endocrine neoplasia type 1 (MEN1, OMIM 131100) is an autosomal dominant inherited
syndrome caused by germline mutations in the MEN1 gene that predisposes carriers to variable
risk of development of tumors in diverse non-endocrine and endocrine organs. The main
MEN1-related endocrine tumors affect the parathyroid and pituitary glands, pancreatic islets and
duodenal endocrine cells. Most MEN1 carriers develop main tumors between 5 and 80 years
with at least one them initiating around 20–30 years (50–60%) and, invariably, 94% of MEN1
carriers have developed one or more disease manifestations at the age of 50 years. MEN1 is
associated with decreased life expectancy, which in 75% of patients is caused by disorder-related
morbidity/mortality (1). Different clinical protocols have been recommended to allow the early
diagnosis and treatment of MEN1-related tumors in MEN1 mutation carriers (1–7). Although
the Clinical Practice Guidelines for MEN1 has recommended periodic vigilance initiating at 5, 8,
and 10 years of age (1), respectively, for pituitary adenoma, primary hyperparathyroidism (HPT)
and neuroendocrine pancreatic tumors, there are only a few papers emphasizing clinical features,
management and treatment of children and adolescents with MEN1 (3, 8–13).
In the present issue of the Frontiers in Endocrinology, this topic was widely discussed by two
independent research groups (Kamilaris and Stratakis; de Laat et al.). Kamilaris and Stratakis
presented an updated and complete review on the genetics and molecular pathogenesis, including
indications for performing the MEN1 mutational analysis, diagnosis and treatment of the main
MEN1-related tumors in young patients. These authors revisited a number of papers addressing
the occurrence of these tumors at young ages, reinforcing the importance and the pivotal role of
periodic biochemical and radiological surveillance of MEN1 carriers (Kamilaris and Stratakis).
The DutchMEN group critically debated the current clinical diagnosis of MEN1, emphasizing
the different outcomes of true MEN1 cases harboring MEN1 mutations and phenocopies. The
latter group is defined as, (i) MEN1-like phenotypes harboring germline mutations in other genes
(AIP or CDKIs genes), and (ii) mutation-negative cases secondary to sporadic and casual co-
occurrence of two MEN1 tumors (de Laat et al.). Also, these authors suggested less strict strategies
of vigilance for phenocopies. In addition, de Laat et al. reported that a scenario of late MEN1
diagnosis involving MEN1 index cases and family members is yet highly prevalent in developed
countries. Importantly, both the low rate of clinical suspicion of MEN1 by clinicians and the
delayed genetic testing of family members of MEN1 patients were associated with higher morbidity
andmortality. The prompt recognition of suspected clinical features by clinicians, accessible genetic
testing, centralization and monitoring of MEN1 care through national registries were useful in
Netherlands to diagnose MEN1 earlier (de Laat et al.).
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As mentioned, the study of MEN1 in children and adolescents
is still limited. Recently, Marx and Lourenço debated diverse
questions and controversies on HPT occurring in young
MEN1 carriers as parathyroid pathophysiology, the differential
diagnosis of HPT with other hypercalcemic genetic disorders,
the importance of periodic vigilance and early diagnosis, criteria
to indicate early parathyroid surgery and different treatment
strategies (Marx and Lourenço). This debate gains strength
due to the complete penetrance of HPT in MEN1, the high
occurrence of this tumor as the first clinical manifestation and
the frequent presence of HPT in adolescent and young adult
MEN1 patients.
Also, the clinical and surgical experience of the Italian group
in the follow-up and surgery of youngers with MEN1-related
HPT has been recently reported (Marini et al.). These authors
described 19 young MEN1 cases diagnosed with HPT before
20y, the surgical strategies adopted and discussed critically
the risks and benefits of early parathyroidectomy (PTX) in
MEN1, since the ideal timing to indicate PTX in such cases
is still not known (Marini et al.). The same group, in a
retrospective study, emphasized the efficacy reached by the
total PTX (TPTX) approach followed by parathyroid auto-
transplantation in 28 out of 38 HPT/MEN1 patients diagnosed
before the age of 30 y, in comparison with nine other
similar patients submitted to subtotal parathyroidectomy (SPTX)
(Tonelli et al.). In the long-term follow up (11.8 ± 6.6 y),
relatively low rates of recurrence (14 vs. 22%) were observed
when patients were submitted, respectively, to either TPTX
and SPTX, whereas the rate of permanent hypoparathyroidism
was 17.9 vs. 22%, respectively (Tonelli et al.). In addition,
early demineralization was documented in two young MEN1
cases with HPT, followed by recovery of bone mineral density
(BMD) after PTX (Tonelli et al.). These data reinforced previous
findings documenting both the early bone loss in young
HPT/MEN1 cases and the positive impact of PTX on bone
health, leading to a significant BMD increase 12 months after
surgery (14–19).
Recently, a protocol applied to HPT/MEN1 patients followed
up by the MD Anderson Cancer Center was reported including
preoperative evaluation, intraoperative decision-making as to
initial cases and reoperations, and the step by step SPTX
procedures, elected as the preferential surgical approach
(Nobecourt et al.). In 2019, a large Brazilian cohort of 161
HPT/MEN1 patients submitted to PTX between 1987 and
2018 was reported (Montenegro et al.). Among them, 94
patients (58.4%) were operated on between 2011 and 2018
including seven out of nine patients younger than 21 y
(Montenegro et al.). These findings might suggest a tendency
to a recent increase in the number of HPT/MEN1 adolescents
submitted to PTX and they are most probably due to more
accessible genetic testing and active periodic vigilance of MEN1
carriers, contrasting with previous periods (20–22). Furthermore,
based on four adolescent HPT/MEN1 cases that underwent
unintentional less than SPTX, Montenegro et al. debated on the
potential risks and benefits of less extensive PTX procedures
applied to the specific subset of young HPT/MEN1 patients
presenting a documented localized disease. The need for more
extensive studies on this specific topic was stressed (Montenegro
et al.).
In fact, some groups have reported experiences with less
extensive parathyroid surgeries in MEN1, independent of
age (23–27). These protocols might potentially minimize the
risks of hypoparathyroidism in younger MEN1 patients in
which peak bone mass was not yet reached. In contrast,
less extensive PTX procedures would increase the risks
of surgical failure, which may lead to persistent or early
recurrent HPT. However, classical surgical protocols as mostly
SPTX, and also TPTX, remain elective surgeries for MEN1
patients whereas more studies are necessary to validate the
efficacy of less extensive surgeries in young MEN1 cases with
HPT (Tonelli et al.; Nobecourt et al.; Montenegro et al.)
(28–36).
Recently, Dantas et al. described a young MEN1 patient
presenting hydrocephalus and intracranial hypertension caused
by a giant prolactinoma as first clinical manifestations of
MEN1. The importance of refining and reaching a more
effective periodic screening program to avoid acute life-
threatening events was mentioned. Also, an extensive review
on giant prolactinoma occurring as part of MEN1 was
offered (Dantas et al.).
Conversely, two research groups from Italy and Brazil
collaborated in this topic in Frontiers in Endocrinology amplifying
the strict spectrum of original studies on MEN1-related tumors
occurring at young ages suggesting potential peculiarities of the
management and treatment of such cases (Marini et al.; Tonelli
et al.; Montenegro et al.; Dantas et al.). However, due to the rarity
of this disorder and the few studies focusing on a large number of
affected young MEN1 carriers, is not surprising the adoption of
divergent protocols of management and treatment by different
expert groups. These data indicate that more studies should
be warranted to optimize strategies of follow-up, attempting
to reach more secure and effective decision-making concerning
treatment of the young patients with MEN1 syndrome.
Thus, overall, the papers of Kamilaris and Stratakis, de Laat
et al., Marx and Lourenço, Nobecourt et al. updated, commented
and transmitted important experiences attempting to amplify
our knowledge on the present Research Topic in Frontiers
in Endocrinology.
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